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Background:Machado–Joseph Disease (MJD), a form of dominantly inherited ataxia belonging to the group of
polyQ expansion neurodegenerative disorders, occurs when a threshold value for the number of glutamines in
Ataxin-3 (Atx3) polyglutamine region is exceeded. As a result of its modular multidomain architecture, Atx3 is
known to engage in multiple macromolecular interactions, which might be unbalanced when the polyQ tract
is expanded, culminating in the aggregation and formation of intracellular inclusions, a unifying ﬁngerprint of
this group of neurodegenerative disorders. Since aggregation is speciﬁc to certain brain regions, localization-
dependent posttranslational modiﬁcations that differentially affect Atx3 might also contribute for MJD.
Methods:We combined in vitro and cellular approaches to address SUMOylation in the brain-predominant Atx3
isoform and assessed the impact of this posttranslational modiﬁcation on Atx3 self-assembly and interaction
with its native partner, p97.
Results:We demonstrate that Atx3 is SUMOylated at K356 both in vitro and in cells, which contributes for de-
creased formation of amyloid ﬁbrils and for increased afﬁnity towards p97.
Conclusions and general signiﬁcance: These ﬁndings highlight the role of SUMOylation as a regulator of Atx3 func-
tion, with implications on Atx3 protein interaction network and self-assembly, with potential impact for further
understanding the molecular mechanisms underlying MJD pathogenesis.© 2015 Elsevier B.V. All rights reserved.1. Introduction
Ataxin-3 (Atx3) is the protein responsible for Machado–Joseph
Disease (MJD), a form of dominantly inherited ataxia belonging to the
group of polyglutamine (polyQ) expansion neurodegenerative disor-
ders. It displays a modular organization, which includes an N-terminal
catalytic Josephin domain (JD)with deubiquitinase activity, two ubiqui-
tin interacting motifs (UIMs), the expandable polyQ tract, and a
C-terminal region that may include an additional UIM, depending on
the splice isoform [1]. The physiological role of Atx3, which is located
both in the cellular nucleus and cytoplasm [2–4], is still not welliologia Molecular e Celular,
ro).
uímica e Biológica, 2780-157understood, although it has been linked to ubiquitin-mediated path-
ways implicated in protein quality control and maintenance of protein
homeostasis [5–7], in transcriptional regulation [8], in cytoskeleton
regulation [9], and in myogenesis [10]. Similar to what occurs in other
polyQ-expansion disorders, self-assembly and aggregation of the
polyQ-expanded Atx3 represent important hallmarks of MJD. Early
in vitro studies showed that expansion of the Atx3 polyQ tract within
the pathological range induced the formation of insoluble, β-rich ﬁbrils
capable of binding amyloid-speciﬁc dyes [11]. Later it was demonstrat-
ed that non-pathological Atx3 and the JD alone could form not only
ﬁbrillar aggregates under destabilizing conditions [12–14] but also
soluble aggregates under native-like conditions [15], revealing an
important role for protein regions/domains outside the polyQ tract
in Atx3 aggregation and indicating that the protein context can inﬂu-
ence polyQ-mediated aggregation [15,16]. As a result of its modular
multidomain structure, Atx3 is known to engage in multiple macromo-
lecular interactions and there is evidence that it associates with a
wide range of functional multiprotein complexes, frequently in a
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other polyQ-expansion diseases, is believed to result from an imbalance
in the association of the polyQ-expanded protein with its molecular
partners, leading to exposure of aggregation-prone regions and culmi-
nating in Atx3 self-assembly and functional alterations [18,19]. Further-
more, cell-speciﬁc occurrence of Atx3 posttranslational modiﬁcations
may alter Atx3 macromolecular interaction networks, intracellular
protein dynamics, protein folding, stability, activity and, consequently
its function [2,20–22], thereby contributing to neuroselective MJD
pathogenesis.
To date, several posttranslational modiﬁcations have been associat-
ed with polyQ disease proteins, including ubiquitination, phosphoryla-
tion, acetylation, transglutamination, palmitoylation and SUMOylation
[23]. Atx3was shown to be a substrate for ubiquitination, amodiﬁcation
that was reported to enhance its proteolytic activity [24]. SUMOylation,
the covalent attachment of small ubiquitin-like modiﬁer (SUMO) pro-
tein, is also known to inﬂuence several aspects of a target protein,
including activity, localization and stability [20]. SUMO attachment
may promote or interfere with protein–protein interactions bymasking
existing binding sites, by creating new interfaces, or by inducing confor-
mational changes [20], with functional consequences depending on the
substrate and cellular environment. This covalentmodiﬁcation has been
demonstrated to occur for several polyQ-containing proteins, such
as huntingtin [25], ataxin-1 [26], and ataxin-7 [27]. The causative pro-
tein of Huntington's disease (HD) is known to be SUMOylated or
ubiquitinated at a single lysine residue. In a Drosophila model of
HD, these two modiﬁcations show strikingly different phenotypes:
ubiquitination of huntingtin decreases neurodegeneration,whilemod-
iﬁcation by SUMO has the opposite effect [25]. Similarly, SUMOylation
promotes the aggregation of polyQ-expanded ataxin-1, increasing its
pathogenicity [28]. In contrast, SUMOylation appears to reduce the
aggregation propensity of polyQ-expanded ataxin-7 and androgen re-
ceptor [27,29], underscoring the role of the substrate and of the cellular
context in the effect of this posttranslational modiﬁcation. Here we in-
vestigated the ability of Atx3 to be SUMOylated either in vitro or in
cells and the functional impact of this posttranslational modiﬁcation.
2. Materials and methods
2.1. Expression plasmids
Oligonucleotides used throughout the work are listed in Table S1.
The cDNAs for human Atx3 isoforms 3UIM (13Q), 2UIM (13Q) and
3UIM (77Q) were cloned into the pDEST17 Gateway vector (Life Tech-
nologies, Carlsbad, CA, USA) as previously described [15]. Plasmids for
the expression of SUMO1, E1 (Uba2 and Aos1) and E2 (Ubc9) were
kindly provided by Dr. Chongwoo A. Kim (University of Texas Health
Sciences Center, USA) and for ScULP1 by Prof. M. Margarida Oliveira
(GPlantS, ITQB-UNL, Portugal). Site-directed mutagenesis with the
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies,
Santa Clara, CA, USA) was used to produce the mature form of SUMO2
by introducing a stop codon downstream of Gly95, in an expression
plasmid kindly provided by Prof. Keith Wilkinson (Emory University
School ofMedicine, USA). The same site-directedmutagenesis approach
was used to introduce a cleavage site for recombinant tobacco etch virus
(TEV) protease between the open reading frame and the N-terminal se-
quence coding for the 6xHis tag in all Atx3-encoding vectors [30], and to
introduce point mutations in putative-SUMOylation sites. Vector
pQEp97ND1 encoding the N and D1 domains of p97 and the vector
harboring the ubiquitin-6xHis gene fusion were kind gifts from Dr. Di
Xia (National Cancer Institute, USA) and Prof. Patrick Loll (Drexel Uni-
versity College of Medicine, USA) [31], respectively. Eukaryotic expres-
sion plasmid pEYFP-C1 encoding an N-terminal fusion of the yellow
ﬂuorescent protein (YFP) with human SUMO-1 was obtained from Dr.
Mary Dasso (National Institute for Child Health and Human Develop-
ment, USA) through Addgene (Cambridge, MA, USA, catalog no.13380). The eukaryotic expression plasmid pcDNA3 encoding Ubc9,
provided by Dr. Rainer Niedenthal (Medizinischen Hochschule Hanno-
ver, Germany) [32], was used to generate a fusion construct with
human 3UIM Atx3 at the C-terminal of Ubc9 (pcDNA-Ubc9-MCS-
atx3). The vector pIC111 was a kind gift from Dr. Iain Cheeseman
(Whitehead Institute for Biomedical Research, USA) and was used to
clone 3UIM Atx3 upstream GFP sequence, generating vector pIC111-
GFP-3UIMAtx3.
2.2. Protein expression and puriﬁcation
Escherichia coli BL21(DE3)-SI cells (Life Technologies, Carlsbad, CA,
USA) were transformed with Atx3-encoding vectors and 6xHis-tagged
proteins were expressed and puriﬁed as previously described [15].
Puriﬁed protein (in 20 mM sodium phosphate pH 7.5, 200 mM NaCl,
5% (vol/vol) glycerol, 2 mM EDTA, 1 mM DTT) was analyzed by SDS-
PAGE and by analytical size exclusion chromatography (SEC) on a
Superose 12 10/300 GL column (GE Healthcare, Little Chalfont, UK)
and concentrated on centrifugal ultraﬁltration devices (10 kDa cutoff;
Merck Millipore, Darmstadt, Germany). Expression of Uba2, Aos1,
Ubc9, ScULP1, and of mature forms of SUMO1 and SUMO2 was carried
out in E. coli BL21(DE3) cells following similar procedures as for Atx3
variants, but using 0.4 mM of isopropyl β-D-1-thiogalactopyranoside
(IPTG) to induce expression. Ubc9, SUMO1, and ScUPL1 were puriﬁed
by immobilized metal afﬁnity chromatography (IMAC) on a HisTrap
Chelating column (GE Healthcare, Little Chalfont, UK). Fractions eluted
in buffer containing 250 mM imidazole were dialyzed against 10 mM
Tris–HCl pH 7.5, 50 mM NaCl, and 20% (vol/vol) glycerol (Ubc9 and
ScULP1) or 10% (vol/vol) glycerol and 1mMDTT (SUMO1), and concen-
trated on centrifugal ultraﬁltration devices (3 kDa cutoff; Merck
Millipore, Darmstadt, Germany). E. coli protein extracts containing
Uba2 and Aos1 were mixed and incubated for 1 h at 4 °C to promote
the formation of the E1 heterodimer (Uba2/Aos1). The E1 heterodimer
was then puriﬁed in a 2-step process consisting of IMAC (HisTrap Che-
lating, as above) followed by SEC (Sephacryl S-200 HR, GE Healthcare,
Little Chalfont, UK), with 20 mM Tris–HCl pH 7.5, 50 mM NaCl, and
20% (vol/vol) glycerol as the mobile phase, to separate individual free
subunits from the heterodimer. The purest fractions were pooled and
concentrated on centrifugal ultraﬁltration devices (10 kDa cutoff;
Merck Millipore, Darmstadt, Germany). Untagged mature SUMO2
protein was loaded onto an Econo-Pac High Q anion exchange car-
tridge (Bio-Rad, Hercules, CA, USA) equilibrated with 30 mM Tris–
HCl pH 7.5, 1mMDTT, and 2.5mMEDTA and eluted with a linear gra-
dient of NaCl (0–350 mM) in the same buffer. Fractions containing
SUMO2were pooled and puriﬁed by SEC on a HiPrep 16/60 Sephacryl
S-100 HR column (GE Healthcare, Little Chalfont, UK) equilibrated in
30 mM Tris–HCl pH 7.5, 250 mM NaCl, 1 mM DTT, 2.5 mM EDTA, and
10% (vol/vol) glycerol. The purest fractions were pooled and concen-
trated on centrifugal ultraﬁltration devices (3 kDa cutoff; Merck
Millipore, Darmstadt, Germany). The protein fraction comprising the
N and D1 domains of p97 were expressed and puriﬁed as previously
described [33].
2.3. Western blotting
Samples were separated on 12% or 15% (wt/vol) polyacrylamide
SDS-PAGE gels and electrotransferred onto polyvinylidene ﬂuoride
membranes (Merck Millipore, Darmstadt, Germany), which were then
blocked with TBS-Tween (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.1%
(vol/vol) Tween-20) with 5% (wt/vol) non-fat dry milk. Primary
antibodies were incubated with membranes for 1 h at room tempera-
ture or overnight at 4 °C. The following primary antibodies were used:
rabbit polyclonal anti-Atx3 that recognizes the JD domain peptide
HKTDLERMLEAND and therefore detects both 3UIM (Uniprot P54252-
2) and 2UIM (Uniprot P54252-1) Atx3 variants (1:2000; kindly provid-
ed by Dr. P. Maciel [34]), 1H9 mouse monoclonal anti-Atx3 (1:10,000;
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anti-Ub (1:1000; Dako, Agilent Technologies, Santa Clara, CA, USA),
mouse monoclonal anti-His (1:10,000; GenScript, Piscataway, NJ,
USA), rabbit polyclonal anti-SUMO1 (1:1500; Boston Biochem, Cam-
bridge, MA, USA) and anti-SUMO2/3 (1:2000; Boston Biochem, Cam-
bridge, MA, USA), clone N86/38 mouse monoclonal anti-GFP
(1:1000, NeuroMab, Davis, CA, USA) and mouse monoclonal anti-β-
tubulin (1:400,000; Sigma-Aldrich, St. Louis, MO, USA). Secondary
antibodies (alkaline phosphatase-conjugated goat polyclonal anti-
rabbit (1:10,000; Sigma-Aldrich, St. Louis, MO, USA) and goat poly-
clonal anti-mouse (1:10,000; GenScript, Piscataway, NJ, USA) were
incubated with membranes for 1 h and detection was performed
with ECL Plus reagent (GE Healthcare, Little Chalfont, UK). All anti-
bodies were diluted in TBS-Tween with 0.5% (wt/vol) non-fat dry
milk. Atx3 was detected in cellular extracts with ECF (GE Healthcare,
Little Chalfont, UK) and membranes were scanned with a Storm 860
Gel and Blot Imaging System (GE Healthcare, Little Chalfont, UK).
Membranes were then stripped (0.2 M NaOH, 15 min) and reprobed
with the anti-GFP antibody.
2.4. In vitro and in situ SUMOylation assays
In vitro SUMOylation assays were adapted from a published protocol
[35], using 2 μg puriﬁed Atx3, 0.4 μg SUMO1 or 0.5 μg SUMO2, 2 μg E1,
0.8 μg E2, 0.4 U creatine phosphokinase (Sigma-Aldrich, St. Louis, MO,
USA), 10 mM creatine phosphate (Sigma-Aldrich, St. Louis, MO, USA)
and 0.6 U inorganic pyrophosphatase (Sigma-Aldrich, St. Louis, MO,
USA) in 50 mM Tris–HCl pH 7.6, 50 mM KCl, 5 mM MgCl2, and 1 mM
DTT. The reaction was started with the addition of 2 mM ATP, allowed
to proceed for 20–90 min at 37 °C, and stopped with 5 μL 4× SDS-PAGE
loading buffer. The samples were analyzed by Western blotting, using
speciﬁc anti-SUMO1, anti-SUMO2, and polyclonal anti-Atx3 antibodies.
For de-SUMOylation assays, SUMOylation assay samples were incubated
with 1mMDTT for 5min at room temperature, before 1–5 μg ScULP1was
added and allowed to react for 30 min at 37 °C. Reactions were stopped
and analyzed as described for the SUMOylation assays. For large-scale
production of SUMOylated Atx3, the assay was scaled 20-fold. The
SUMOylated protein was applied to a MonoQ HR 5/5 column (GE
Healthcare, Little Chalfont, UK) pre-equilibrated with 50 mM sodium
phosphate buffer pH 7.5. Bound proteinswere elutedwith the same buff-
er containing 200 mM NaCl and concentrated by ultraﬁltration as de-
scribed above. Excess unmodiﬁed 3UIM Atx3 protein eluting earlier
from the ion-exchange column was also collected, concentrated and
used as a control to compare with the SUMOylated protein.
To test Atx3 SUMOylation in cells, COS-7 cells were grown in
Dulbecco's modiﬁed eagle medium supplemented with 10% (vol/vol)
fetal bovine serum and 1% (wt/vol) penicillin/streptomycin at 37 °C
in 5% (vol/vol) CO2. One day prior to transfection, fully conﬂuent
COS-7 cells were diluted 1:6 and seeded onto MW6 plates. Transient
transfection was performed using Effectene (Qiagen, Venlo, The
Netherlands), according to the manufacturer's indications (2 μg of
DNA per well; 2 μg of each plasmid for co-transfection), followed by
24 h incubation. Culture medium was then removed and transfected
cells were directly scraped in 60 μl of 1:1 RIPA buffer (25 mM Tris–
HCl pH 7.6, 150 mM NaCl, 1% (wt/vol) NP-40, 1% (wt/vol) sodium
deoxycholate, 0.1% (wt/vol) SDS) and 2× SDS-PAGE loading buffer.
Samples were then brieﬂy sonicated, separated on a 10% (wt/vol) poly-
acrylamide SDS-PAGE gel, electroblotted and probed with monoclonal
anti-Atx3 and anti-GFP antibodies.
2.5. Cortical neuron culture preparation and transfection
Cortical neuronal cultureswere prepared as previously described [36].
Brieﬂy, the cortices of Wistar rat embryos with 18 days were dissected,
trypsinized and resuspended in a neuronal plating medium (minimum
essential medium – MEM – supplemented with 10% (wt/vol) horseserum, 0.6% (wt/vol) glucose and 1 mM sodium pyruvate). Cells were
passed through a 0.2 μm ﬁlter and then seeded onto 15 mm coverslip-
containing 12 well culture plates, at 2.5 × 105 cells/well. 2–4 h later the
plattingmediumwas substituted with Neurobasal medium supplement-
ed with 2% SM1, 0.5 mM glutamine and 0.12 mg/ml gentamycin. Cells
were kept in an incubator at 37 °C, with a humidiﬁed atmosphere con-
taining 5% CO2, up to 8 days in vitro (DIV).
At 4 DIV cultures were transfected by a calcium phosphate transfec-
tion procedure adapted from a previously described protocol [37], with
4 μg of plasmid pIC111-GFP-3UIMAtx3, with an additional 4 μg of plas-
mid pcDNA-Ubc9 in the case of co-transfection. Cells were incubated for
1.5 h, after which the transfection medium was substituted by the
previously-reserved conditioned neuronal culture medium. Kynurenic
acid (2 mM) was used throughout the transfection procedure in order
to block ionotropic glutamate receptors. Expression was left to occur
for 4 DIV under normal cell culture incubation conditions.
For Western blot probing of endogenous Atx3, cortical neurons cul-
tured at 9x105 cells/well in 6-well plates were stimulated at 9 DIV with
10 mM N-ethylmaleimide (NEM) for 30 min (or alternatively with the
vehicle ethanol) and immediately processed and analyzed by Western
blot as described for the in situ SUMOylation assays.
2.6. Atx3 activity assays
Protease activity assays were carried out at 30 °C using 100–500 nM
Atx3 and 200 nM Ub-AMC in 50 mM HEPES pH 7.5, 0.5 mM EDTA, and
1 mM DTT and monitored (380 nm excitation, 460 nm emission) for
5 min in a Fluoromax-4 spectroﬂuorometer (Horiba, Kyoto, Japan). For
the release of ubiquitin from a ubiquitin–6xHis fusion protein [31],
Atx3 was incubated with ubiquitin-6xHis in 50 mM HEPES pH 7.5,
0.5 mM EDTA, and 1 mM DTT at 37 °C. The reaction was stopped at
different time points by the addition of SDS-PAGE loading buffer
and the proteins separated by SDS-PAGE. To determine the percent-
age of ubiquitin release, SDS-PAGE gel bandswere quantiﬁed by den-
sitometry. Density of free ubiquitin and uncleaved ubiquitin-6xHis at
each time point was normalized against the average of the density of
either unmodiﬁed Atx3 or SUMOylated Atx3. Percentage of ubiquitin
was calculated as [free ubiquitin / (uncleaved ubiquitin-6xHis + free
ubiquitin) × 100].
2.7. Circular dichroism spectroscopy
CD measurements were performed on a Jasco-815 spectrometer
(Jasco Inc, Easton, MA, USA) using 1 mm-path length quartz cuvettes.
Proteins were diluted to 1.3 μM in 20 mM sodium phosphate pH 7.5,
20 mM NaCl, 0.5% (vol/vol) glycerol, 0.1 mM DTT and 0.1 mM EDTA.
The secondary structure content was calculated by spectral decomposi-
tion with the CDSSTR method [38].
2.8. Aggregation kinetics
Ataxin-3 amyloid formation kinetics was monitored by following
the increase in thioﬂavin-T ﬂuorescence as previously described [15,
39]. Brieﬂy, ﬂuorescence at 480 nm (440 nm excitation)wasmonitored
at 37 °C every 30 min over a period of 500 h for samples containing
30 μM thioﬂavin-T and 5 μM protein in 20 mM sodium phosphate
pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% (vol/vol) glycerol, and 1 mM
DTT in a FluoDia T70 (Photon Technology International, Edison, NJ,
USA) microplate ﬂuorimeter. To prevent evaporation, each reaction
was overlaid with 20 μl parafﬁn oil. Data were analyzed using Prism 5
(GraphPad Software).
For visualization of protein ﬁbers/aggregates by TEM protein sam-
ples were diluted in water and adsorbed onto glow-discharged,
carbon-coated ﬁlms supported on 200-mesh copper grids and negative-
ly stainedwith 2% (wt/vol) uranyl acetate. Gridswere visualized using a
JEM-1400 (JEOL, Tokyo, Japan) TEM at an accelerating voltage of 80 kV.
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Transfected cortical neuronswith 8 DIVwere ﬁxed with 4% (wt/vol)
paraformaldehyde and 4% (wt/vol) sucrose in PBS, for 15 min at RT.
Counting of Atx3-GFP aggregate-containing neurons was performed
blindly to condition by manually scanning coverlips and observing
the GFP ﬂuorescence with a Zeiss Axiovert 200 M microscope (Carl
Zeiss AG, Oberkochen, Germany) using a 63× oil objective (Plan-
Apochromat, 1.4 numeric amplitude). Aggregation was expressed
as the fraction of cells containing aggregates.
2.10. Differential scanning ﬂuorimetry
The thermal stability of Atx3 samples (20 μM) was assessed by
following SYPRO Orange (Agilent Technologies, Santa Clara, CA, USA)
ﬂuorescence using a cy3 ﬁlter on an iCycler iQ Real Time PCR Detection
System (Bio-Rad) as a function of temperature (35 to 85 °C in 0.5 °C
increments). The melting curves were analyzed using CFX Manager
(Bio-Rad, Hercules, CA, USA).
2.11. Surface plasmon resonance
SPR experimentswere performed at 25 °C using a BIACORE 3000 (GE
Healthcare, Little Chalfont, UK) equipped with a research-grade CM5
sensor chip. Atx3, either SUMOylated (3UIM Atx3 S1, 56 kDa) or unmod-
iﬁed 3UIM Atx3 (44 kDa) was used as ligand and immobilized using
amine-coupling chemistry. The surfaces of all four ﬂow cells were activat-
ed for 7 min with a 1:1 mixture of 0.1 M NHS (N-hydroxysuccinimide)
and 0.1 M EDC (3-(N,N-dimethylamino) propyl-N-ethylcarbodiimide) at
a ﬂow rate of 5 μl/min. The ligands (10 μg/ml in 10 mM sodium acetate
pH 4.5)were immobilized at a density of 1500 RU. Bovine serum albumin
(BSA)was immobilized on ﬂow cell 1, serving as the reference surface. All
surfaces were blocked with a 7 minute injection of 1 M ethanolamine
pH 8.5. To collect kinetic binding data, p97 ND1 (hexameric, 318 kDa)
was diluted in 10 mM HEPES pH 7.4, 150 mM NaCl, and 0.005% (vol/
vol) P20 and injected over the four ﬂow cells at concentrations of 0.125,
0.25, 0.5, 2, 4, 8, 16 and 32 nM at a ﬂow rate of 30 μl/min. The complex
was allowed to associate and dissociate for 180 and 300 s, respectively.
The surfaceswere regeneratedwith a 40 μl injection of 1M ethanolamine
pH 8.5 at 5 μl/min. Data were ﬁt to a simple 1:1 interaction model using
the global data analysis option available within BIAevaluation software
(GE Healthcare, Little Chalfont, UK).
2.12. Statistical analysis
The arithmetic means are given with standard deviation with 95%
conﬁdence value. Statistical analyses were carried out using indepen-
dent samples t-test analysis. A P value less than 0.05 was considered
to denote a signiﬁcant difference.
3. Results
3.1. Atx3 is SUMOylated in vitro and in mammalian cells
To determine the susceptibility of Atx3 to SUMO attachment, an
in vitro SUMOylation assay was established using recombinant 3UIM
Atx3 (Atx3 variant 2 containing 3 UIM motifs, UniProt accession code
P54252-2), E1 and E2 enzymes, SUMO1 or SUMO2, and ATP. This assay
yielded a higher molecular weight band that could be detected with an
anti-Atx3 antibody, displaying a time-dependent increase in intensity
(Fig. 1A).
This Atx3-containing band, observedwhen either SUMO1 or SUMO2
was added to the reaction, was also reactive to an anti-SUMO antibody
(Fig. S1), had a molecular weight compatible with the covalent attach-
ment of SUMO to Atx3 and disappeared upon incubation with the
deSUMOylase ULP1 (Fig. 1B). Since there are different splice variantsof Atx3 with different properties and displaying distinct C-termini
(Fig. 1C) [40], the SUMOylation of the 2UIM Atx3 variant (Atx3 variant
1 containing only 2 UIM motifs, UniProt accession code P54252-1)
was also investigated. Contrary to what was observed for the 3UIM
Atx3 isoform, no in vitro SUMOylation was detected when using 2UIM
Atx3 (Fig. 1D). These results suggested that SUMOylation is speciﬁc to
3UIM Atx3, with SUMO attachment occurring at the variable
C-terminal portion of Atx3, downstream from the polyQ tract. Atx3
SUMOylation was also evaluated in a cellular system. COS-7 cells were
co-transfected with a plasmid encoding the SUMO-conjugating enzyme
Ubc9 fused to the N-terminus of 3UIM Atx3 and a plasmid encoding
YFP-SUMO1, a widely used strategy for increasing the SUMOylation
levels of speciﬁc targets [32,41,42]. The cell lysates were probed for
Atx3, revealing three high-molecular weight bands when Ubc9-3UIM
Atx3 was co-expressed with YFP-SUMO1 (Fig. 1E), showing that 3UIM
Atx3 was also SUMOylated in cells, and indicating that SUMO attach-
ment might occur in at least three sites, as SUMO1 does not have the
ability to form polymeric chains [43]. Importantly, a high molecular
weight band compatible with SUMOylation of Atx3 in more than one
site is also observed in the in vitro reaction (Fig. 1A). Furthermore, in
non-transfected cortical neuron extracts obtained after stimulation
with the deSUMOylase inhibitor N-ethylmaleimide (NEM), the appear-
ance of a protein band recognized by the anti-Atx3 antibody can be ob-
served, consistent with the presence of endogenous Atx3 conjugated to
SUMO (Fig. S2). Unsurprisingly, this band is extremely faint, in agree-
ment with the expected low fraction of Atx3 conjugated to SUMO.
3.2. 3UIM Atx3 is modiﬁed by SUMO at K356
The unique C-terminal portion of 3UIM Atx3 contains three lysine
residues (K356, K360 and K361), which could be potentially modiﬁed
by SUMOylation. To further narrow the search for the SUMOylation
site(s), a truncated form of 3UIM Atx3 (1–352, Fig. 1C) was tested and
shown not to be SUMOylated in vitro (Fig. 2A), indicating that SUMO at-
tachment occurs in at least one of those three C-terminal lysine resi-
dues. Using a single point mutant (K356R) and a double mutant
(K360R/K361R) it was shown that K356 is the major site for
SUMOylation for both SUMO1 and SUMO2 proteins and that in vitro
SUMOylation at K356 is independent of the presence of either K360 or
K361 (Fig. 2A). The occurrence of speciﬁc SUMO attachment at 3UIM
Atx3 K356was also tested in COS-7 cells using Ubc9-3UIM Atx3 chime-
ra, a strategy that already proved to be useful in assessing SUMOylation
of protein candidates such as FOS, CRSP9, CDC37, CSNK2B, TAF10,
HSF2BP, PSMC3 and DRG1 [41]. In accordance with the in vitro results,
3UIM Atx3 was found to be SUMOylated at K356 in COS-7 cells
(Fig. 2B). In order to understand the relevance of polyQ expansion in
the SUMOylation process of Atx3, the same experimental methodolo-
gies were applied to 3UIM Atx3 (77Q), revealing that this protein is
also SUMOylated at K356 in a cellular environment (Fig. 2C) as well as
in vitro using strictly monomeric proteins (Fig. 2D and E).
Of note, we found that K166, a previously described Atx3
SUMOylation site identiﬁed in Atx3 expressed in HEK293 cells [45],
is not the main SUMOylation site neither in vitro nor in COS-7 cells,
since the K166R mutation, contrary to what was observed in the
K356R mutant, did not impair SUMOylation using our assay (Fig. 2B
and C). This is in good agreement with the observation that JD alone
(Fig. S3) and 2UIM Atx3 (Fig. 1D), both lacking K356 but containing
K166, are not SUMOylated. Taken together, these results unambiguously
demonstrate that the brain-predominant Atx3 isoform is preferentially
SUMOylated within the C-terminal tail K356 both in vitro and in cells.
3.3. Structural impact of SUMOylation on Atx3 thermal stability, proteolytic
activity and ﬁbril formation
In order to assess the functional and structural impact of Atx3 mod-
iﬁcation by SUMO, the enzymatic SUMOylation assay was successfully
Fig. 1.Atx3 is efﬁciently SUMOylated by SUMO1 and SUMO2 at the C-terminal tail. (A)Western blot analysis of in vitro 3UIMAtx3 SUMOylation. Puriﬁed Atx3was incubatedwith SUMO1
or SUMO2, in the presence of human SUMOylation machinery (E1 and E2 enzymes) and 2 mM ATP, for 20–90 min at 37 °C. ATP was omitted in the negative control. A band with a mo-
lecularmass compatiblewithmono-SUMOylated Atx3 (~64 kDa, i.e. 20 kDa higher than unmodiﬁed Atx3) could be detectedwith an anti-Atx3 antibody. Black arrowhead indicates a band
compatible to SUMOylation in more than one site. (B) Western blot analysis of 3UIM Atx3 SUMOylation reaction products in the presence (1 or 5 μg) or absence of the SUMO-speciﬁc
protease ULP1. The band corresponding to SUMOylated Atx3 could not be detected when the reactionwas carried out in the presence of ULP1, suggesting that themodiﬁcation is speciﬁc.
For negative controls, either ATP or Atx3was omitted. (C) Schematic representation of the splice isoforms of Atx3, 2UIM Atx3 and 3UIMAtx3, and of a C-terminal truncated form of 3UIM
Atx3 used in this work. (D) Western blot analysis of the in vitro SUMOylation reaction products of puriﬁed 2UIM Atx3, performed as described in (A). No SUMOylated Atx3-compatible
bandswere observed using an anti-Atx3 antibody. (E)Western blot analysis of cellular extracts fromCOS-7 cells expressing the fusion proteinUbc9-3UIMAtx3, YFP-SUMO1or co-expressing
Ubc9-3UIM Atx3with YFP-SUMO1. Atx3 SUMOylation bands (~100 kDa, ~140 kDa and ~180 kDa) could be detected when Ubc9-3UIMAtx3 (~62 kDa) was co-expressed with YFP-SUMO1
(37 kDa). The experiment was performed in 4 independent preparations.
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oped. The SUMOylated material from a large-scale assay (~10 mg of
freshly puriﬁed Atx3 protein) was separated from unmodiﬁed Atx3 by
anion-exchange chromatography (Fig. 3A) and the unmodiﬁed Atx3
(uAtx3) was used as control in subsequent experiments, as it was
exposed to the same treatment as the SUMO-conjugated protein.
SUMOylated Atx3 (Atx3:S1) could be efﬁciently puriﬁed using this e-
xperimental approach (Fig. 3B and C). The melting temperatures of un-
modiﬁed Atx3 (13Q), expanded Atx3 (77Q) and Atx3:S1 were
determined by differential scanning ﬂuorimetry. As previously shown
[46], polyQ expansion did not modify the overall thermal stability of
monomeric Atx3 and, surprisingly, no signiﬁcant changes were ob-
served upon SUMOylation (Table 1).
Indeed, circular dichroism (CD) measurements revealed that
SUMO attachment had no major inﬂuence on the overall secondary
structure content of Atx3, since the CD spectrum of SUMOylated
Atx3 superimposes with the spectrum of an equimolar mixture of
unmodiﬁed Atx3 and SUMO1 and with the spectrum resulting from
adding together the independently obtained spectra of unmodiﬁed
Atx3 and SUMO1 (Fig. 3D). Additionally, the proteolytic activity of
SUMOylated Atx3 was assessed by determining its ability to release
ubiquitin from an ubiquitin-6xHis fusion. SUMOylation does notsigniﬁcantly inﬂuence the proteolytic activity of Atx3 in this assay
(Fig. 3E), in line with the results obtained from activity assays using a
ﬂuorogenic substrate (ubiquitin-AMC; Fig. S4). Altogether these results
indicate that SUMOylation does not inﬂuence the overall secondary
structure of Atx3 nor its thermal stability or proteolytic activity.
The impact of SUMOylation on the aggregation behavior of Atx3was
also assessed by monitoring thioﬂavin-T binding, an assay that reports
the ﬁrst JD-dependent step of Atx3 assembly into amyloid-like struc-
tures [39,47]. Even though SEC analysis revealed nodifferences between
the initial oligomerization statuses of SUMOylated or unmodiﬁed Atx3
(Fig. 4A), with both proteins behaving as monomeric species, there is
a divergent aggregation proﬁle of SUMOylated Atx3 when compared
to the unmodiﬁed protein, with SUMO attachment being sufﬁcient to
reduce the total number of Thioﬂavin-T positive Atx3 protoﬁbrils
(Fig. 4B). Complementary aggregation monitoring by TEM revealed no
differences in ﬁber morphology between SUMOylated and unmodiﬁed
Atx3, or an obvious decrease in pre-ﬁbrillar structures in the modiﬁed
Atx3 sample at the beginning of the assay that could justify the
differences in the aggregation proﬁle (Fig. 4C). This indicates that
SUMOylation has an impact on Atx3 self-assembly. To evaluate the im-
pact of SUMOylation in the aggregation of Atx3 in neuronal cells, Ubc9
was overexpressed in cultured cortical neurons and the aggregation of
Fig. 2. PolyQ-expanded and non-expanded 3UIM Atx3 is SUMOylated at K356 both in vitro and in COS-7 cells. (A). Western blot analysis of in vitro SUMOylation of 3UIM Atx3 (13Q), a
truncated form of 3UIM Atx3 (Atx3 1–352), 3UIM Atx3 K356R mutant and 3UIM Atx3 K360R/K361R double mutant. Proteins were incubated with SUMO1 or SUMO2, as described in
Fig. 1A. Only the C-terminal K356R mutation abolished SUMOylation indicating that 3UIM Atx3 is modiﬁed at K356 by both SUMO1 and SUMO2. (B) Fusions of Ubc9 and 3UIM Atx3
or its K356R, K166R, or K166R/K356R mutants were co-expressed with YFP-SUMO1 in COS-7 cells and cellular protein extracts were separated by SDS-PAGE and probed with anti-
Atx3 or anti-YFP antibodies. Single mutation of K166 to arginine was not enough to hinder 3UIM Atx3 SUMOylation in COS-7 cells, as opposed to both the K356R mutant and the
K166R/K356R double mutant. SUMOylation of 3UIM Atx3 K356R was assessed in three independent experiments. (C) Fusions between Ubc9 and 3UIM Atx3 (77Q) or its K356R,
K166R, or K166R/K356R mutants were co-expressed with YFP-SUMO1 in COS-7 cells and analyzed as in panel B. Mutations K356R and K166R/K356R abolished the appearance of a
band corresponding to SUMOylated Atx3. (D) PolyQ-expanded (77Q) and non-expanded (13Q) 3UIM Atx3 isoforms (black and blue, respectively) are monomeric. Both Atx3 isoforms
elute as monomers, on analytical SEC, as previously described [15,44]. (E) Western blot analysis of the in vitro SUMOylation reaction products of 3UIM Atx3 (77Q) and its K356R mutant
showed that the polyQ-expanded Atx3 is modiﬁed by SUMO1 and SUMO2 and that the K356R mutation abolished this modiﬁcation.
1955B. Almeida et al. / Biochimica et Biophysica Acta 1852 (2015) 1950–1959GFP-Atx3 assessed by microscopy (Fig. S5). These results demonstrate
that stimulation of SUMOylation leads to a reduction in the percentage
of cells displaying Atx3 aggregates (Fig. 4D).
3.4. SUMOylation modulates the afﬁnity of Atx3 for the ATPase p97
Numerous cellular processes are known to be regulated by protein
SUMOylation, with SUMO modifying the interaction surface of the tar-
get protein, blocking existing interactions and/or promoting new ones[20]. One of the well-characterized Atx3-interacting partners is the
AAA+ ATPase p97 (a.k.a. valosin-containing protein — VCP), that
binds to the Lys/Arg-rich binding motif preceding the polyQ tract of
Atx3 through the region encompassing the N and D1 domains [48]. Sur-
face plasmon resonance (SPR) analysis of the interaction between full
length unmodiﬁed Atx3 and p97 (the region comprising the N and D1
domains, p97 ND1) revealed that both proteins interact with an afﬁnity
in the low nanomolar range (1.2 nM, Fig. 5A, Table 2). The binding data
could be ﬁtted to a 1:1 stoichiometric model, consistent with the
Fig. 3. SUMOylation has no impact on Atx3 secondary structure and does not alter signiﬁcantly its proteolytic activity. (A) In vitro SUMOylation of Atx3was scaled up and SUMO-modiﬁed
Atx3 was puriﬁed by anion exchange chromatography. SUMOylated Atx3 (abbreviated as Atx3:S1) was efﬁciently separated from unmodiﬁed Atx3 (from hereon named uAtx3).
(B) Puriﬁed proteins (Atx3:S1 and uAtx3) were separated by SDS-PAGE and the gel stained with Coomassie Blue. (C) SUMOylated Atx3 was efﬁciently puriﬁed as revealed by West-
ern-blot analysis using both anti-Atx3 and anti-SUMO1 (anti-S1) antibodies. (D) Far-UV CD spectra of unmodiﬁed Atx3 (blue), SUMOylated Atx3 (red), SUMO1 (green), an equimolar
mixture of unmodiﬁed Atx3 and SUMO1 (uAtx3 + SUMO1 mix; grey) and the arithmetic sum of the independent spectra of unmodiﬁed Atx3 and SUMO 1 (uAtx3 + SUMO1; black).
(E) Time course of cleavage of ubiquitin-6His substrate [31] by unmodiﬁed and SUMOylated Atx3. Triplicate assays were performed independently and the results of a representative ex-
periment are presented. Blue arrowhead indicates unmodiﬁed Atx3; red arrowhead indicates SUMOylated Atx3. Graph on the right represents the densitometric quantiﬁcation of ubiq-
uitin released at each time point by unmodiﬁed Atx3 or SUMOylated Atx3. Each bar refers to the normalized percentage of cleaved ubiquitin, presented with standard deviation.
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agreement with the stoichiometries determined for other
deubiquitinases with afﬁnity for the p97 N-domain [49].
Quantiﬁcation by SPR of the impact of Atx3 SUMOylation on its in-
teractionwith p97ND1 (Fig. 5B) revealed that the two proteins interact
strongly (kDwithin the nM range, Table 2) and that the covalent attach-
ment of SUMO to Atx3 results in a twofold increase in association rate
(ka of 1.05 × 106 1/Ms vs 5.93 × 105 1/Ms, Table 2) and afﬁnity for
p97 ND1 (kD of 0.66 nM vs 1.23 nM, Table 2). Moreover, the complex
formed with SUMOylated Atx3 is somewhat more stable than that of
the unmodiﬁed Atx3 (kd of 6.85 × 10−4 1/s versus 7.28 × 10−4 1/s,
Table 2). Interestingly, SUMO conjugation did not modify the interac-
tion of Atx3 with CHIP, a protein known to interact with the C-
terminal tail of Atx3 [50,51] (Fig. S6), further highlighting the speciﬁc
effect of Atx3 SUMOylation on the interaction with p97. Altogether,
these results indicate that Atx3 interacts with p97 ND1with nanomolar
afﬁnity and SUMOylation at K356 positively modulates complex
formation.
4. Discussion
Recent evidence supports the idea that MJD results from a combina-
tion ofmultiple events triggered by the expansion of Atx3polyQ tract [1,
17,52], which culminate in the formation of toxic oligomers and ulti-
mately in neuronal death. Due to the ability of Atx3 to associate with
a wide range of functional multiprotein complexes, and since regions/
domains outside the polyQ tract greatly inﬂuence Atx3 aggregation
behavior [14,15,30,39,53,54], it is hypothesized that self-assembly ofTable 1
Melting temperatures of Atx3 variants.
3UIMAtx3 (13Q) 3UIMAtx3 (77Q) Atx3:S1
Tm (°C) 50.0 ± 0.2 52.0 ± 0.1 51.1 ± 0.3polyQ-expanded Atx3 can result from an imbalance in the association
with the nativemolecular partners, whose interactionsmight be further
modulated by posttranslational modiﬁcations [17,18]. Here it is shown
that both non-pathogenic and expanded Atx3 are SUMOylated at
K356 and that only the 3UIMAtx3 splice isoform,which is predominant
in the brain [40], but not the 2UIM Atx3 isoform, is SUMOylated, sug-
gesting that this posttranslational modiﬁcation might have a role in
the control of Atx3 neuronal functions, therefore impacting MJD.
It is known that Atx3 has an intrinsic propensity to self-assemble
through a multistep pathway, with the JD playing a preponderant role
in the ﬁrst oligomerization step, common to both normal and disease-
related Atx3 [1,15], and the polyQ-expanded region mediating the
formation of stable SDS-insoluble ﬁbrils [39,55]. We demonstrate that
covalent attachment of SUMO to the C-terminal K356 of Atx3 is able
to decrease its intrinsic propensity for self-assembly, inﬂuencing the
JD-dependent aggregation step, and likely having an impact on MJD.
One possible explanation is that SUMOylation induces subtle alterations
in the JD surface implicated in Atx3 self-assembly [53], which is sufﬁ-
cient to reduce the overall amount of ﬁbrils formed. Overexpression of
Ubc9 in cultured neurons decreases the fraction of cells displaying
Atx3 aggregation, suggesting that stimulating SUMOylation leads to a
decreased aggregation of Atx3 in a biologic context. Further studies
will elucidate if the effect is due to increased SUMO conjugation to Atx3.
SUMOylation is known to modulate the functional properties of a
target protein, particularly by changing the overall macromolecular in-
teraction surface and consequently the afﬁnity for native molecular
partners [56]. Atx3molecular functions relying on interactions targeting
Atx3 C-terminal region [17] are therefore expected to be affected by this
posttranslational modiﬁcation. Our data demonstrate that SUMOylation
does not signiﬁcantly modulate Atx3 ubiquitin hydrolase activity, in
contrast to what was shown for Atx3 monoubiquitination within the
JD [24]. However, it has an impact on the interaction of Atx3 with p97,
an AAA+ hexameric ring-shaped ATPase involved in several essential
biological processes, such as post-mitotic homotypic membrane fusion
Fig. 4. SUMOylation decreases Atx3 ﬁbril formation in vitro. (A) SUMOylated Atx3 (Atx3:S1) and unmodiﬁed Atx3 (red and blue, respectively) are monomeric as analyzed by size-exclu-
sion chromatography. (B) Protein aggregationmonitored by thioﬂavin-T ﬂuorescence for SUMOylated Atx3 (Atx3:S1) and unmodiﬁed Atx3 (red and blue, respectively). Curves represent
the average of 4 independent assays with standard deviation. *P ≤ 0.05, t-test, n=4. (C) Protein samples were collected at the stationary phase (~270 h), and evaluated by TEM revealing
no differences in ﬁber morphology between SUMOylated and unmodiﬁed Atx3. Scale bar corresponds to 200 nm. (D) Rat cortical neuron cultures were transfected with GFP-tagged
human Atx3 (3UIM Atx3) with or without co-transfection with Ubc9 (3UIM Atx3 + Ubc9) and ﬁxed 4 days later. The number of cells with Atx3-GFP aggregates was counted versus
the number of cells presenting only diffuse Atx3-GFP signal. Graph represents the percentage of cells displaying Atx3-GFP aggregates with standard deviation. *P ≤ 0.05, t-test, n= 4.
Fig. 5. SUMOylation modulates the afﬁnity of Atx3 for p97. The interaction between p97
ND1 and (A) unmodiﬁed Atx3 or (B) SUMOylated Atx3 (Atx3:S1) was characterized by
surface plasmon resonance (SPR). Atx3 proteins were immobilized on the surface of
CM5 sensor chips and p97 ND1 was used as the analyte. Colored lines correspond to SPR
signal (expressed as resonance units, RU) upon injection of distinct concentrations of
p97 ND1. Black lines correspond to a simple 1:1 ﬁtting interaction model (calculated ki-
netic constants are listed in Table 2) using the global data analysis option available within
BIAevaluation software.
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the degradation of soluble and membrane proteins by the ubiquitin–
proteasome system [58,59]. p97 coordinatesmultiple cellular pathways,
depending on its interaction partners [60], whose association can be
modulated by an array of posttranslational modiﬁcations [61]. More-
over, p97 is found in ubiquitinated protein inclusions in a number of
neurodegenerative disease states, including those resulting from
polyQ expansions [62]. Despite its presence in multiple polyQ-protein
inclusions, p97 does not interact with the polyQ-tract itself, but it was
shown to speciﬁcally bind to Atx3 [48], although no quantitative data
on the interaction of p97 with full-length Atx3 had been previously de-
termined. We demonstrate that unmodiﬁed Atx3 binds to p97 with
high afﬁnity, in the low nanomolar range. p97 is thus the tightest Atx3
interaction partner identiﬁed so far, and one of the few proteins
targeting solely the Atx3 C-terminal tail in the proximity of the
disease-related polyQ expansion site [17]. Interestingly, SUMOylation
not only increases the afﬁnity of Atx3 for p97, but also promotes a faster
association. Themechanism bywhich SUMO conjugation to Atx3might
increase the afﬁnity to p97 remains unclear. Even though SUMO1 does
not directly interact in vitro with p97 (Fig. S7), analysis of the amino
acid sequence of p97 reveals the presence of a putative SUMO-
interacting motif (SIM) sequence, 429LIDL432 [63,64]. Therefore, one
possible explanation is that binding to Atx3 may provide an anchoring
site and orient the SUMO protein for optimal interaction with p97Table 2
Kinetic values for the interaction of p97 ND1with Atx3 variants (Atx3:S1 and unmodiﬁed
Atx3).
ka (1/Ms) kd (1/s) Rmax (RU) kD (nM) Chi2
Atx3:S1 1.05E + 06 6.85E−04 42.2 0.66 1.92
uAtx3 5.93E + 05 7.28E−04 45.1 1.23 1.24
ka, association rate constant; kd, dissociation rate constant; Rmax,maximal response; KD,
dissociation constant.
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natively, one cannot discard the existence of a second p97-binding site
in Atx3 that becomes available upon covalent attachment of SUMO to
the C-terminal region of Atx3. SUMOylation of Atx3 and a consequent
modiﬁcation of its afﬁnity towards p97 are expected to have an impact
on the biological function of both proteins. Both Atx3 and p97 share a
role on protein degradation pathways [65]. While p97 is speciﬁcally
involved in the extraction of polyubiquitinated proteins from the ER to
the cytosol, Atx3 functions as an ubiquitin chain-editing enzyme [65].
Interestingly, Atx3 seems to decrease the interaction of p97 with
ubiquitinated proteins by competing with Ufd1, a p97 molecular part-
ner involved in ER-associated degradation (ERAD) [7]. This suggests
that Atx3might function as amodulator of ER-associated protein degra-
dation by controlling p97-dependent protein extraction from the ER [7].
Considering that the afﬁnity of p97 for the Ufd1/Npl4 heterodimer is in
the low micromolar range (2.1 μM) [66], thus approximately 1700-fold
lower than the afﬁnity for unmodiﬁed Atx3, and the high intracellular
p97:Atx3 ratio, it is tempting to speculate that Atx3 might be playing
a preponderant role on a large number of cellular processes mediated
by p97. Atx3 SUMOylationmay then act as a signal to trigger association
with p97, adding a new level of regulation in the p97-mediated ER-
associated protein degradation process.
p97 was also shown to inﬂuence the aggregation of a polyQ-
expanded Atx3 fragment in vitro and to modulate neurodegeneration
in a Drosophila melanogaster disease model [48]. Surprisingly, this effect
was dependent on the concentration of p97, with low concentrations
stimulating the self-assembly and neurotoxicity of the Atx3 fragment
and high concentrations suppressing those effects. Given the inﬂuence
of Atx3 SUMOylation on the afﬁnity towards p97, it is tempting to
speculate that this posttranslational modiﬁcationmight be contributing
for a decrease in Atx3 self-assembly, either directly by reducing the JD-
mediated self-assembly step or indirectly, through the promotion of a
faster and stronger association with p97, mimicking the Atx3 aggrega-
tion–suppression phenomenon observed for high concentrations of
p97 [48]. The exact determination of the cellular conditions that favor
Atx3 SUMOylation and binding to p97 is therefore relevant to elucidate
the potential role of the interplay between this posttranslational modi-
ﬁcation and molecular interactions for MJD therapy.Transparency document
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